XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payments - SOP 2015 (Details) - SOP 2015 - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 23, 2017
Aug. 25, 2016
Sep. 23, 2015
Apr. 02, 2015
Options                
Outstanding at beginning of year (in shares)     3,044,899          
Forfeited (in shares)     (117,879)          
Outstanding at end of year (in shares) 2,927,020   2,927,020          
Vested and exercisable at end of year (in shares) 1,485,557   1,485,557          
Weighted average exercise price in $ per share                
Outstanding balance at beginning of year (in dollars per share)     $ 8.35          
Forfeited (in dollars per share)     8.05          
Outstanding balance at end of year (in dollars per share) $ 8.36   8.36          
Vested and exercisable balance at end of year (in dollars per share) $ 7.98   $ 7.98          
Additional disclosures                
Share-based compensation expense $ 0.4 $ 1.1 $ 1.3 $ 2.9        
Options                
Share-Based Payments                
Vesting period     4 years          
Exercise period     10 years          
Additional disclosures                
Weighted-average remaining contractual life     7 years 10 months 24 days          
Total unrecognized compensation related to non-vested options (in dollars) $ 7.6   $ 7.6          
Period of recognition of total unrecognized compensation related to options     1 year 1 month 6 days          
Options | First year                
Share-Based Payments                
Vesting period     1 year          
Percentage that vests during the period     25.00%          
Options | Second, third, and fourth years                
Share-Based Payments                
Percentage that vests during the period     75.00%          
Monthly vesting percentage     2.083%          
Nabriva Therapeutics plc ("Nabriva Ireland") | Redomiciliation Transaction | Ordinary Shares                
Share-Based Payments                
Number of shares to be awarded for each option when exercised         10      
Nabriva Therapeutics AG ("Nabriva Austria") | Common Stock                
Share-Based Payments                
Maximum number of shares authorized           346,235 177,499 95,000
Nabriva Therapeutics AG ("Nabriva Austria") | Redomiciliation Transaction | Common Stock                
Share-Based Payments                
Number of shares to be awarded for each option when exercised         1